Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited treatment options.
• Activating KRAS mutations drive over 90% of PDAC cases, influencing tumor growth and treatment resistance.
• KRAS was historically considered undruggable, hindering therapeutic progress.

Purpose of the Study:

• To review the recent advances in targeting KRAS in pancreatic cancer.
• To discuss the potential of novel KRAS-directed therapies and combination strategies.
• To highlight the shift towards molecularly guided treatments for PDAC.

Main Methods:

• Review of preclinical models and early-phase clinical trials of KRAS inhibitors.
• Analysis of emerging combination strategies involving KRAS-targeted agents.
• Exploration of novel therapeutic approaches like KRAS degradation and RNA-targeted therapies.

Main Results:

• KRAS is now a druggable target with allele-specific and pan-RAS(ON) inhibitors.
• These therapies demonstrate significant antitumor activity and tumor microenvironment modulation.
• Evidence suggests delayed development of therapeutic resistance.

Conclusions:

• Targeting KRAS represents a paradigm shift in PDAC treatment.
• Combination strategies are crucial for enhancing treatment depth and durability.
• Molecularly guided therapies offer a promising future for PDAC patients with unmet needs.